Table 1.
Characteristics of the meta-analyzed datasets
| Dataset | IMSGC UK* | IMSGC US* | Gene MSA CH* | Gene MSA NL* | Gene MSA US* | ANZ† | BWH/TT§ |
|---|---|---|---|---|---|---|---|
| Number of individuals (cases/controls) | 453/2950 | 342/1679 | 253/208 | 230/232 | 486/431 | 1618/1988 | 2313/4857 |
| Clinical characteristics (cases only) | |||||||
| Female:Male Ratio | 3.0:1:0 | 3.2:1.0 | 2.8:1.0 | 2.9:1.0 | 3.1:1.0 | 2.6:1 | 2.6:1 |
| Mean Disease Duration, years (range) | 11 (0–40) | 16 (<1–36) | 12 (<1–58) | 13 (<1–39) | 15 (1–59) | NA | 14 (2–53)/5(0–33)‡ |
| Mean age at onset, years (range) | 27 (10–48) | 29 (11–50) | 33 (8–59) | 33 (13–71) | 33 (1–70) | 34 (7–67) | 33 (9–60)/30 (8–54) ‡ |
| Genotypic and analysis characteristics | |||||||
| Genotyping platform | Affy 500K | Affy 500K | Illumina 550 | Illumina 550 | Illumina 550 | Cases: Illumina Hap370CNV Controls: Illumina Infinium |
Affy 6.0 |
| Analyzed individuals (cases/controls)a | 449/2928 | 341/1679 | 251/208 | 225/228 | 477/425 | 1616/1987 | 2186/4698 |
| Genomic inflation factor (lambda) | 1.029 | 1.034 | 1.04 | 1.026 | 1.029 | 1.061 | 1.054 |
*
Analyzed in our previous meta-analysis 2
†
Analyzed in the ANZgene Study4
§
Analyzed in part in our previous meta-analysis.3 The dataset used in De Jager et al. has 860 subjects with MS from BWH and their 1720 matched healthy controls.
‡
Values are for BWH cases and TT cases separately.
NA: not available
a
Analyzed cases and controls per dataset after Quality Control.